单位:[1]Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA[2]Department of Lung Cancer, Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China[3]Beijing ACCB Biotech Ltd., Beijing 100084, China[4]Department of Oncology, Beijing Friendship Hospital of Capital Medical University, Beijing 100050, China临床科室肿瘤中心肿瘤内科首都医科大学附属北京友谊医院[5]Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China河北医科大学第四医院
Adenocarcinoma is the most common type of lung cancer. Epithelial-mesenchymal transition (EMT) is required for tumor invasion/metastasis and the components that control this process are potential therapeutic targets. This study we examined the role of Gli in lung adenocarcinoma and whether its activation regulates metastasis through EMT in lung adenocarcinoma. We found that tumors with high Gli expression had significantly lower E-Cadherin expression in two independent cohorts of patients with lung adenocarcinoma that we studied. In vitro up-regulation of SHh resulted in increased cell migration while small molecule inhibitors of Smo or Gli significantly reduced cell mobility both in a wound healing assay and in a 3D cell invasion assay. Inhibition of Gli in vivo decreased tumor growth and induced an increase in E-Cadherin expression. Our results indicate that Gli may be critical for lung adenocarcinoma metastasis and that a novel Gli inhibitor shows promise as a therapeutic agent by preventing cell migration and invasion in vitro and significantly reducing tumor growth and increasing E-Cadherin expression in vivo.
基金:
NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA125030]; Eileen D. Ludwig Endowed for Thoracic Oncology Research; Bonnie J. Addario Lung Cancer Foundation; Ziegelmam Family Foundation; Barbara Isackson Lung Cancer Research Fund; Key Program for Anti-cancer Research of Tianjin Municipal Science and Technology Commission [12ZCDZSY15400]; Science & Technology Support Project of Hebei Province [132077127D]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501983]; Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley & Oberman Foundation; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA125030] Funding Source: NIH RePORTER
第一作者单位:[1]Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Li Hui,Yue Dongsheng,Jin Joy Q.,et al.Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas[J].ONCOTARGET.2016,7(49):80415-80425.doi:10.18632/oncotarget.11246.
APA:
Li, Hui,Yue, Dongsheng,Jin, Joy Q.,Woodard, Gavitt A.,Tolani, Bhairavi...&He, Biao.(2016).Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas.ONCOTARGET,7,(49)
MLA:
Li, Hui,et al."Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas".ONCOTARGET 7..49(2016):80415-80425